688177 Bio-Thera Solutions,
- 23.79
- -0.41-1.69%
Bio-Thera Solutions, News
Bio-Thera Solutions, Ltd.'s (SHSE:688177) Last Week's 8.7% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
Biotech 2024 Third Quarter Report
bio-thera solutions (688177.SH) releases performance for the first three quarters, with a net loss of 0.365 billion yuan
Bio-Thera Solutions (688177.SH) released the report for the first three quarters of 2024. During the reporting period, the company achieved revenue of 5...
Bio-Thera Solutions (688177.SH): a net loss of 0.365 billion yuan in the first three quarters.
GeLongHui October 29 | Bio-Thera Solutions (688177.SH) announced that in the first three quarters of 2024, revenue reached 0.581 billion yuan, a year-on-year increase of 26.11%; net income attributable to shareholders of the listed company was -0.365 billion yuan, with a basic earnings per share of -0.88 yuan.
Bocom Intl: Guangzhou launches first batch of innovative drugs and medical devices catalog, focusing on innovation and consumer properties as symbols.
Following the introduction of policies encouraging the innovation of pharmaceuticals, the latest innovative drug and medical device product catalog released by Guangzhou will further provide full-chain, all-field support to the high-quality development of the biomedical industry.
Star Evening News | Minmetals New Energy, Bio-Thera Solutions, and 6 other companies announced their shareholding reduction plans. Vertical and horizontal shares receive an administrative supervision decision letter from Sichuan Securities Regulatory Bure
1. Guangdong may introduce demonstration clauses for technology insurance such as biomedical and integrated circuits; 2. Shenzhen: Accelerating the establishment of a multi-billion-dollar Shenzhen semiconductor and integrated circuit industry investment fund; 3. The Shanghai Stock Exchange terminates the listing and issuance review of Feixiang Technology on the Star Market.
Bio-Thera Solutions Enters Up to $110 Million Licensing Deal With Gedeon Richter
Express News | Hungary's Richter Says Bio-Thera Will Receive an Upfront Payyment of 8.5 Million USD -Statement
Express News | Hungary's Richter Says Bat2206 Is a Biosimilar Candidate to Stelara (Ustekinumab) -Statement
Express News | China's Bio-Thera and Hungary's Richter Execute Exclusive Commercialization Agreement for Bat2206 for EU Countries, UK, Switzerland and Other Countries
Bio-Thera Solutions (688177.SH) has granted the commercialization rights of BAT2206 injection to Girui Pharmaceuticals in exclusive areas on a paid licensing basis.
bio-thera solutions (688177.SH) announced that the company has signed a strategic collaboration agreement with Gedeon Richter Plc....
Bio-Thera Solutions, Ltd. (SHSE:688177) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Bio-Thera Solutions (688177.SH): Therabio has not reduced its shareholding upon the expiration of the Fanwan Lake reduction plan.
Bio-Thera Solutions (688177.SH) announced that the company received a notice from shareholder Thera on September 24, 2024.
Would Bio-Thera Solutions (SHSE:688177) Be Better Off With Less Debt?
Bio-Thera Solutions, Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE, An Approved Biosimilar Referencing Tocilizumab In Arthritis Research & Therapy
Bio-Thera Solutions 2024 Semi-Annual Report
Bio-Thera Solutions 2024 Semi-Annual Report Summary
August 23rd A-share Lightning Rod | CMST Development: Shareholder CLH 12 (HK) Limited intends to reduce its shareholding by no more than 3%; Bio-Thera Solutions: Net loss of 0.237 billion yuan in the first half of the year.
CMST Development shareholder CLH 12 (HK) Limited plans to reduce its shareholding by no more than 3%; Guodian Nanjing Automation expressed its intention to sell no more than 28.4198 million shares of CSSC Science & Technology held; 34.7 million shares of CSSC Science & Technology's restricted shares will be lifted on August 23; Shanghai New Power Automotive Technology reported a net loss of 689 million yuan in the first half of the year; bio-thera solutions reported a net loss of 237 million yuan in the first half of the year.
Bio-Thera Solutions' Cancer Drug Gets EU Marketing Approval
Express News | European Medicines Agency (EMA) Approves Bio-Thera Solutions' Bat1706 (Avzivi®, Bevacizumab), a Biosimilar Referencing Avastin®
Analysis
Price Target
No Data
No Data